Inmune Bio, Inc. (INMB) · Oct 21, 2026 · Other events
UK filing accelerated — Potential UK approval about six weeks sooner
INmune Bio signs an Ebstrocel commercialization agreement while replacing its UK rolling filing with a full February 2027 application.
INmune Bio is a late-stage biotechnology company trying to move Ebstrocel from manufacturing and regulatory preparation toward its first commercial market, while XPro remains a separate late-stage pipeline program. Recent manufacturing progress and MHRA alignment had already put Ebstrocel near the registration stage.
The regulatory path has improved, but the submission date itself moves later. INmune is replacing the rolling UK submission planned for late 2026 with one complete MAA targeted for February 2027. 〔0〕 The company says the consolidated approach could bring potential UK approval forward by roughly six weeks, but that remains conditional on MHRA validation, review and information requests. 〔1〕
The filing advances commercial readiness without creating revenue yet. The Uniphar agreement gives INmune a framework for named-patient supply in selected European and MENA markets and could provide storage, distribution, treatment-site onboarding and related services. However, implementation depends on country-specific statements of work, applicable law, approvals, pricing and reimbursement; Ebstrocel remains investigational, so this is infrastructure rather than a commercial launch or booked sales.
The U.S. plan becomes the next major regulatory branch. INmune is preparing an FDA Type B meeting request and now targets a BLA in the second quarter of 2027, subject to FDA feedback. 〔2〕 That creates a clearer 2027 regulatory sequence, but no agency has accepted the proposed approval timing.
Bottom line: This is executional progress toward commercialization, not an approval or revenue event. The UK route looks more efficient and international access is being built, but the agreement has no disclosed economics and the key outcomes remain regulatory decisions.
Full UK MAA submission, early February 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!